Forte Biosciences Inc (OQ:FBRX)
Business Focus: Bio Therapeutic Drugs
Mar 18, 2024 04:05 pm ET
Forte Biosciences, Inc. Announces 2023 Results and Provides Business Update
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced its 2023 results and provided a business update.
Dec 01, 2023 04:01 pm ET
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules.
Nov 13, 2023 04:01 pm ET
Forte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business Update
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced third quarter 2023 results and provided a business update.
Sep 14, 2023 10:50 am ET
ISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company’s Upcoming Annual Meeting
Camac Partners, LLC (“Camac”) and ATG Capital Management, LLC (“ATG”) (together with the other participants in their solicitation, the “Concerned Stockholders,” the “Group” or “we”), which collectively own approximately 8.5% of the outstanding common stock of Forte Biosciences, Inc. (Nasdaq: FBRX) (“Forte” or the “Company”), today announced that leading independent proxy advisory firms Institutional Shareholder Services Inc. (“ISS”) and Glass, Lewis & Co., LLC (“Glass Lewis”) have recommended stockholders support boardroom change at the Company’s upcoming Annual Meeting of Stockholders (the “A
Sep 06, 2023 03:15 pm ET
Concerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Company’s Boardroom
Camac Partners, LLC (“Camac”) and ATG Capital Management, LLC (“ATG”) (together with the other participants in their solicitation, the “Concerned Stockholders,” the “Group” or “we”) collectively own approximately 8.5% of the outstanding common stock of Forte Biosciences, Inc. (Nasdaq: FBRX) (“Forte” or the “Company”). Today, the Group and its independent director candidates – Michael Hacke and Chris McIntyre – responded to misrepresentations and distortions included in the Company’s recent presentation. Messrs. Hacke and McIntyre have been nominated by the Group for election to Forte’s Board o
Aug 25, 2023 08:00 am ET
Concerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to Stockholders
Camac Partners, LLC (“Camac”) and ATG Capital Management, LLC (“ATG”) (together with the other participants in their solicitation, the “Concerned Stockholders,” the “Group” or “we”), who collectively own approximately 8.5% of the outstanding common stock of Forte Biosciences, Inc. (Nasdaq: FBRX) (“Forte” or the “Company”), today announced that they have filed a definitive proxy statement with the U.S. Securities and Exchange Commission (the “SEC”) in connection with Forte’s 2023 Annual Meeting of Stockholders (the “Annual Meeting”) scheduled for September 19, 2023. In addition, the Group sent
Aug 14, 2023 04:01 pm ET
Forte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business Update
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune and autoimmune-detailed diseases, today announced second quarter 2023 results and provided a business update.
Aug 01, 2023 04:01 pm ET
Forte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced key R&D updates for FB-102 and the closing of financing to support the advancement of FB-102.
Jun 20, 2023 08:00 am ET
Jasper Therapeutics Appoints Scott Brun, M.D., to its Board of Directors
Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on the development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria (CSU), lower to...
May 19, 2023 04:01 pm ET
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules.
May 15, 2023 04:01 pm ET
Forte Biosciences, Inc. Announces First Quarter 2023 Results and Provides Business Update
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced first quarter 2023 results and provided a business update.
Mar 31, 2023 04:05 pm ET
Forte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business Update
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced full year 2022 results and provided a business update.
Jan 12, 2023 04:05 pm ET
Mr. David Gryska Appointed to Forte Biosciences Board of Directors
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), announced today that Mr. David Gryska has been appointed to the Forte Biosciences Board of Directors.
Nov 14, 2022 04:01 pm ET
Dr. Scott Brun, M.D. Appointed to Forte Biosciences Board of Directors
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), announced today that Dr. Scott Brun, M.D. has been appointed to the Forte Biosciences Board of Directors.
Nov 14, 2022 04:01 pm ET
Forte Biosciences, Inc. Announces Third Quarter 2022 Results and Provides Business Update
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced third quarter 2022 results and provided a business update.
Aug 17, 2022 08:00 am ET
Camac Partners Condemns Forte Biosciences’ Seemingly Defensive and Unjustifiable Capital Raise
Camac Partners, LLC (together with its affiliates, "Camac" or “we”), which is one of the largest shareholders of Forte Biosciences, Inc. (Nasdaq: FBRX) (“Forte” or the “Company”), today expressed concerns regarding the Company’s sizable trading price discount relative to its cash on hand and the Board of Directors’ (the “Board”) decision to conduct a highly dilutive equity capital raise following the emergence of four separate Schedule 13D filers.
Aug 15, 2022 04:05 pm ET
Forte Biosciences, Inc. Announces Second Quarter 2022 Results and Provides Business Update
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced second quarter 2022 results and provided a business update.
Jun 07, 2022 09:00 am ET
Forte Biosciences, Inc. Announces the Appointment of Dr. Hubert Chen, MD as Chief Scientific Officer and President
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases announces that Dr. Hubert Chen, MD has joined the company as Chief Scientific Officer and President.
Jun 07, 2022 09:00 am ET
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules.
May 16, 2022 09:00 am ET
Forte Biosciences, Inc. Announces First Quarter 2022 Results and Provides Business Update
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a biopharmaceutical company focused on autoimmune diseases, today announced first quarter 2022 results and provided a business update.
Sep 09, 2021 06:15 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Forte Biosciences, Inc. – FBRX
Pomerantz LLP is investigating claims on behalf of investors of Forte Biosciences, Inc. (“Forte” or the “Company”) (NASDAQ: FBRX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Sep 08, 2021 08:51 am ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Forte Biosciences, Inc. (“Forte” or “the Company”) (NASDAQ:
Sep 03, 2021 07:42 pm ET
INVESTIGATION REMINDER: The Schall Law Firm Announces It Is Investigating Claims Against Forte Biosciences, Inc. and Encourages Investors With Losses to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Forte Biosciences, Inc. (“Forte” or “the Company”) (NASDAQ:
Sep 03, 2021 02:14 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Forte Biosciences, Inc. - FBRX
NEW YORK, Sept. 3, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Forte Biosciences, Inc. ("Forte" or the "Company") (NASDAQ: FBRX). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Sep 03, 2021 11:10 am ET
Thinking about buying stock in Meta Materials, Cellect Biotechnology, Forte Biosciences, Camber Energy, or Denison Mines?
NEW YORK, Sept. 3, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MMAT, APOP, FBRX, CEI, and DNN.
Sep 02, 2021 04:05 pm ET
Clinical Trial of FB-401 For the Treatment of Atopic Dermatitis Fails to Meet Statistical Significance
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that topline data from its Phase 2 clinical trial of FB-401 for the treatment of atopic dermatitis failed to meet statistical significance for the primary endpoint of EASI-50 (the proportion of patients with at least a 50% impr
Aug 16, 2021 04:05 pm ET
Forte Biosciences, Inc. to Review the Second Quarter 2021 Results and Expects to Announce Topline Data From Phase 2 Clinical Trial of FB-401 for the Treatment of Atopic Dermatitis on Sept. 7
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, will review the second quarter results and, based on the projected timing of database lock and completion of statistical programming and analysis, expects to announce topline data from its Phase 2 clinical trial of FB-401 for the treatment of
Aug 02, 2021 04:01 pm ET
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules.
Jul 12, 2021 04:01 pm ET
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules.
Jul 01, 2021 04:01 pm ET
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules.
May 10, 2021 04:05 pm ET
Forte Biosciences, Inc. Announces First Quarter 2021 Results and Provides a General Business Update
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company announces first quarter 2021 results and provides a general business update on May 10, 2021.
May 03, 2021 04:30 pm ET
Forte Biosciences, Inc. to Announce First Quarter 2021 Results and Provide a General Business Update
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, will be providing first quarter 2021 results and a general business update on May 10, 2021.
Mar 24, 2021 08:00 am ET
Forte Biosciences, Inc. Announces 4Q and Full Year 2020 Results and Provides a General Business Update
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company announces fourth quarter and full year 2020 results and provides a general business update on March 24, 2021.
Mar 17, 2021 04:05 pm ET
Forte Biosciences, Inc. to Announce 4Q and Full Year 2020 Results and Provide a General Business Update
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, will be providing 4Q and full year 2020 results and provide a general business update on March 24, 2021.
Feb 23, 2021 04:01 pm ET
Forte Biosciences, Inc. to Present at the Chardan Annual Microbiome Medicines Summit on March 8th
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today that Paul Wagner, Ph.D., CEO of Forte Biosciences will be presenting at the Chardan Annual Microbiome Medicines Summit on March 8th, 2021.
Feb 18, 2021 04:01 pm ET
Forte Biosciences, Inc. to Present at the Cowen Annual Health Care Conference on March 1st
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today announced that Paul Wagner, Ph.D., CEO of Forte Biosciences will be presenting at the Cowen Annual Health Care Conference on March 1, 2021.
Feb 12, 2021 04:01 pm ET
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules.
Nov 24, 2020 04:05 pm ET
Forte Biosciences, Inc. to Present at the Evercore ISI 3rd Annual HealthCONx Conference on December 3rd
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today announced that Paul Wagner, Ph.D., CEO of Forte Biosciences will be presenting at the Evercore ISI Annual HealthCONx Conference on December 3, 2020.
Nov 16, 2020 04:05 pm ET
Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules.
Nov 10, 2020 04:05 pm ET
Forte Biosciences, Inc. to Present at the Stifel 2020 Virtual Healthcare Conference on November 18th
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today announced that Paul Wagner, Ph.D., CEO of Forte Biosciences will be presenting at the Stifel 2020 Virtual Healthcare Conference.
Nov 09, 2020 04:05 pm ET
Forte Biosciences, Inc. Announces Third Quarter 2020 Results and Provides General Business Update
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced third quarter 2020 financial results and provided a general business update.
Nov 02, 2020 04:30 pm ET
Forte Biosciences, Inc. to Announce Third Quarter 2020 Results on November 9
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that it will release third quarter 2020 results after the market close on November 9, 2020 and will host a conference call at 4:30 pm ET to discuss third quarter 2020 results and to provide a general business update.
Nov 02, 2020 04:05 pm ET
Forte Biosciences Announces Closing of $46.0 Million Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Forte Biosciences, Inc. (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today the closing of its previously announced underwritten public offering of an aggregate of 1,614,035 shares of its common stock, which includes 210,526 shares sold upon the full exercise of the underwriters’ option to purchase additional shares at a public offering price of $28.50 per share, less the underwriting discounts and commissions. All of the shares were offered by Forte. Including the option exercise, the aggregate gross proceeds of the offering were approximately $46.0 million, before ded
Oct 29, 2020 08:00 am ET
Forte Biosciences Announces Pricing of $40.0 Million Public Offering of Common Stock
Forte Biosciences, Inc. (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 1,403,509 shares of its common stock at a price to the public of $28.50 per share. In addition, Forte has granted to the underwriters a 30-day option to purchase up to an additional 210,526 shares of common stock at the public offering price of $28.50 per share, less underwriting discounts and commissions.
Oct 28, 2020 04:09 pm ET
Forte Biosciences Announces Proposed Public Offering of Common Stock
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that it has commenced an underwritten public offering of its common stock. In addition, Forte expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the of
Oct 26, 2020 08:30 am ET
Forte Biosciences, Inc. Announces the FDA Has Granted Fast Track Designation to FB-401 for the Treatment of Atopic Dermatitis
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to FB-401 for the treatment of atopic dermatitis.
Oct 16, 2020 09:00 am ET
Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules.
Sep 29, 2020 09:00 am ET
Forte Biosciences, Inc. Announces First Patient Dosed in the Clinical Trial of FB-401 for the Treatment of Children and Adults With Atopic Dermatitis
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced that the first patient has been dosed in the clinical trial of FB-401 for the treatment of atopic dermatitis.
Sep 09, 2020 04:01 pm ET
Forte Biosciences, Inc. Announces Full Publication of Phase 1/2 Data in Science Translational Medicine
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the publication in Science Translational Medicine of the full results of the Phase 1/2a data for its lead product candidate, FB-401.
Aug 25, 2020 08:30 am ET
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules
Forte Biosciences, Inc. (NASDAQ: FBRX) (www.fortebiorx.com), a clinical-stage biopharmaceutical company, today announced the issuance of an equity inducement award as required by the Nasdaq Stock Market Rules.
Aug 10, 2020 04:00 pm ET
Forte Biosciences, Inc. Announces Second Quarter 2020 Results and Provides General Business Update
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the second quarter 2020 financial results and provided a general business update.
Aug 03, 2020 09:00 am ET
Forte Biosciences, Inc. to Announce Second Quarter 2020 Results on August 10
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced today that it will release second quarter 2020 results after the market close on Monday, August 10, 2020 and host a conference call at 4:30 p.m. ET to discuss second quarter 2020 results as well as to provide a general business updat
Jul 28, 2020 08:30 am ET
Forte Biosciences, Inc. Reports Inducement Grants Under NASDAQ Listing Rules
Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules.
Jun 18, 2020 08:30 am ET
Forte Biosciences, Inc. Announces Issuance of New U.S. Patent
Forte Biosciences, Inc. (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the issuance of its seventh U.S. patent (10,682,379), broadening protection to include methods for culturing gram negative bacteria from the skin. Together with the six U.S. patents previously issued, Forte now has extensive patent protection covering the composition and method of use of our technology focused on inflammatory skin conditions.
Jun 15, 2020 04:15 pm ET
Forte Biosciences, Inc. Announces Closing of Merger With Tocagen
Forte Biosciences, Inc. (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, today announced the closing of its previously announced merger with Tocagen Inc. (previously trading on NASDAQ under the symbol ”TOCA”), under which the stockholders of Forte have become the majority owners of Tocagen, and the operations of Forte and Tocagen have combined. The company will be led by Paul Wagner, Ph.D., as CEO. The new combined company known as Forte Biosciences will commence trading June 16, 2020 on the Nasdaq Capital Market under the trading symbol “FBRX”.
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.